Patient | Biologic Agents/Dosage/Route/Frequency/Combination Use | Followup Period, Mos | Summary of Main Findings/No. Affected Joints/Daily PSL Use at Last Visit |
---|---|---|---|
1 | IFX/300 mg (5 mg/kg)/IV/every 6 weeks/MTX, PSL | 70 | An improvement in arthritis, erythema nodosum, and anterior uveitis; a reduction in daily PSL use/No. affected joints: 0/PSL: 10 mg/day |
2 | IFX/300 mg (5 mg/kg)/IV/every 6 weeks/MTX, PSL | 70 | An improvement in arthritis, erythema nodosum, anterior, intermediate, and posterior uveitis; a reduction in daily PSL use/No. affected joints: 0/PSL: 6 mg/day |
3 | ADA 40 mg/SC/every 2 weeks/MTX, PSL | 12 | An improvement in arthritis; no recurrence in uveitis/No. affected joints: 0/PSL: 0 mg/day |
4 | ETN/12.5 mg (0.4 mg/kg)/SC/twice weekly/MTX | 102 | An improvement in arthritis; maintained uveitis-free/No. affected joints: 0/PSL: not used |
5-1 | *ETN/5.5 mg (0.4 mg/kg)/SC/twice weekly/MTX | 5 | Discontinuation due to an exacerbation of arthritis. |
5-2 | *TCZ/128 mg (8 mg/kg)/IV/every 4 weeks/none | 33 | Discontinuation due to a recurrence of arthritis. |
5-3 | IFX/200 mg (5 mg/kg)/IV/every 4 weeks/MTX | 68 | An improvement in arthritis; maintained uveitis-free/No. affected joints: 0/PSL: not used |
6-1 | *TCZ/160 mg (8 mg/kg)/IV/every 2 weeks/PSL | 2 | Discontinuation due to development of anti-TCZ IgE antibodies. |
6-2 | IFX/200 mg (10 mg/kg)/IV/every 8 weeks/MTX, PSL | 83 | An improvement in erythema nodosum, anterior, intermediate, and posterior uveitis; increased dose of IFX (to 300 mg) and PSL (to 9 mg) due to an exacerbation of arthritis since 57 mos, thereafter, achieved clinical remission; a reduction in daily PSL use/No. affected joints: 0/PSL: 5 mg/day |
↵* Discontinued and switched to the second or third biologic agent. MTX was given orally once a week; cases 4 and 5 were treated without corticosteroids. IFX: infliximab; IV: intravenous; MTX: methotrexate; PSL: prednisolone; ADA: adalimumab; SC: subcutaneous injection; ETN: etanercept; TCZ: tocilizumab; IgE: immunoglobulin E.